期刊
NATURE REVIEWS CANCER
卷 12, 期 4, 页码 278-287出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nrc3236
关键词
-
类别
资金
- Ludwig Institute for Cancer Research (LICR)
- National Health and Medical Research Council, Australia [487922, 1030469]
- Victorian government, Australia
- Cancer Research Institute (CRI), New York, USA
- CRI
The use of monoclonal antibodies (mAbs) for cancer therapy has achieved considerable success in recent years. Antibody-drug conjugates are powerful new treatment options for lymphomas and solid tumours, and immunomodulatory antibodies have also recently achieved remarkable clinical success. The development of therapeutic antibodies requires a deep understanding of cancer serology, protein-engineering techniques, mechanisms of action and resistance, and the interplay between the immune system and cancer cells. This Review outlines the fundamental strategies that are required to develop antibody therapies for cancer patients through iterative approaches to target and antibody selection, extending from preclinical studies to human trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据